Research

Research and Clinical Trials

At this time, the APS Foundation of America provides some funding to APS ACTION and other research groups if they request assistance and we have have the funds available. The following organizations are currently doing research on APS or related diseases. We encourage anyone who qualifies to participate in these clinical studies. By doing so, you could potentially help APS patients in the future!

Antiphospholipid Syndrome Research Labs

Principal Investigator:
Dr. Jason Knight
Michigan Medicine, Ann Arbor, MI

Contact:

BASIC RESEARCH
Sri Yalavarthi, MS
syalavar@med.umich.edu
734-615-1880

CLINICAL RESEARCH
Claire Hoy, BS
MichiganANSWERS@med.umich.edu
734-647-3949

Please visit the Antiphospholipid Syndrome Program section on UofMHealth.org to learn about APS and how to make an appointment at their clinic. The team at Michigan Medicine is working to advance the understanding of the disease process and identify new, sophisticated approaches to the treatment of APS that are both personalized and proactive. The latest information about clinical trials can be found on their website.

APS ACTION Hydroxychloroquine Study (1)

Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*

Contact:
Joann Vega
(212) 774-2795

aPL-positive patients with no history of thrombosis or other systemic autoimmune diseases are randomized to receive hydroxychloroquine or no treatment in addition to their standard regimen. The study involves 11 study visits and 10 phone visits over 5 years.

APS ACTION aPL/APS Registry (2)

Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*

Contact:
Joann Vega
(212) 774-2795

Any aPL-positive patient is included in this clinical database and repository. The study involves 11 study visits and 10 phone visits over 10 years.

Microbiome Study (3)

Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY

Contact:
Joann Vega
(212) 774-2795

aPL-positive patients who are not receiving immunosuppressive treatment is included in this study that seeks to find if any particular intestinal bacteria may trigger aPL production. Participation will involve 3 study visits over a period of 2 months

PROMISSE Study (4)

Principal Investigator:
Dr. Jane Salmon
Hospital for Special Surgery, New York, NY*

Contact:
Anasam Aslam
(212) 774-2115

Pregnant (6-11 weeks preferably, but can usually recruit up to 18 weeks), history of aPL positivity with or without SLE.

AXLN1007 in Antiphospholipid Syndrome (5)

Principal Investigator:
Dr. Doruk Erkan
Hospital for Special Surgery, New York, NY*

Contact:
Joann Vega
(212) 774-2795

Study Title: An Open-Label Proof of Concept Phase IIa Trial of AXLN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
This is an open-label study where patients will receive 12 doses of study drug over 22 weeks for Non-criteria Manifestations of APS (low platelet count, skin ulcers or abnormal kidney function).